HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
49.92
-0.08 (-0.15%)
As of 11:57AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close50.00
Open50.14
Bid49.94 x 2200
Ask49.99 x 28000
Day's Range49.78 - 50.29
52 Week Range37.47 - 52.19
Volume397,378
Avg. Volume1,692,237
Market Cap13.345B
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.11
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.09
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of HOLX earnings conference call or presentation 31-Jul-19 8:30pm GMT

    Q3 2019 Hologic Inc Earnings Call

  • Business Wire

    Hologic to Webcast Presentation at the Morgan Stanley 17th Annual Global Healthcare Conference

    Hologic, Inc. announced today that the Company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY on Tuesday, September 10 at 12:20 p.m.

  • 10 Most Popular Stocks for ESG Funds
    Investopedia

    10 Most Popular Stocks for ESG Funds

    ESG investing is rapidly increasing in popularity and here are ten of the most popular stocks held by ESG funds.

  • Medtronic, Other Medtech Providers Could Face Additional Tariffs
    GuruFocus.com

    Medtronic, Other Medtech Providers Could Face Additional Tariffs

    So far, the levies and prospect of additional tariffs have not cooled investors’ enthusiasm for the shares of industry members Continue reading...

  • Here's Why You Should Invest in Hologic (HOLX) Stock Now
    Zacks

    Here's Why You Should Invest in Hologic (HOLX) Stock Now

    Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

  • RBC Capital: 5 New Stocks Hedge Funds Snapped Up In Q2
    TipRanks

    RBC Capital: 5 New Stocks Hedge Funds Snapped Up In Q2

    Hedge funds have just released their portfolio trades for the second quarter. And now is the time to evaluate these trades for valuable investing insights. Here we focus on one particular aspect of hedge fund activity- new stock additions. That’s using an August 19 report from RBC Capital which analyzes the 2Q19 13f forms of 363 major hedge funds with significant stakes in US equities (single stocks). The firm used this data to pinpoint the top stocks where hedge fund ownership rose the most during 2Q19, in terms of the net number of funds that added new positions.Three names fall in Health Care (including the 1 name- Allergan (AGN)). Another three names fall in Industrials, notes the firm. But there is one key stock worth bearing in mind: “Note that UBER (UBER) does not qualify for this screen as it does not fall in the S&P 500 and it began trading mid way through the 2nd quarter. It was owned by 51 hedge funds at the end of 2Q19” points out the firm.With that being said, let’s take a closer look at five top new stocks hedge funds are making a bet on right now: 1\. Align Technology (ALGN)Align Technology is leading an orthodontics revolution. The company invented the Invisalign- a clear teeth aligner system- that can replace traditional braces. In Q2, 14 new funds bought Align shares- bringing the total value of ALGN shares owned by hedge funds to $1,805 million. Unfortunately however the stock has declined in both Q2 and Q3. Despite strong Q2 earnings results, the company’s guidance left investors disappointed. "Given the uncertainty in China," CEO Joe Hogan commented, "our outlook for the third quarter reflects a more cautious view for growth in the Asia Pacific region."Don’t be disheartened, says Piper Jaffray’s Matthew O’Brien. This five-star analyst has just reiterated his ALGN buy rating with a $240 price target (37% upside potential). Align "has much better products that will win in the marketplace" he tells investors. O’Brien believes that an accelerated stock repurchase plan of $200 million demonstrates confidence in Align’s outlook.Overall, ALGN shows a Moderate Buy analyst consensus, with an average price target of $259. Interestingly if we look at only the best-performing analysts, this consensus shifts to Strong Buy. 2\. Qualcomm (QCOM)Chip titan Qualcomm is an intriguing hedge fund pick. In the second quarter, 20 more funds owned QCOM stock vs the first quarter. As a result, 15% of the funds covered in RBC Capital’s study now own Qualcomm. Their total holding works out at $1,682 million.Despite numerous problems- most obviously the May 21 antitrust ruling - some analysts do see a bright future ahead. That’s thanks to the company’s prime 5G position. “We believe Qualcomm's bull case is unchanged, with global 5G roll outs expected to increase both royalty income and demand for semiconductors beginning in 2020,” Merrill Lynch’s Tal Liani said recently. “Press reports suggest that all of Apple's 2020 iPhones will contain Qualcomm's 5G chipset, which could drive a 5G cycle across the entire industry.” The analyst has just reiterated his QCOM buy rating and $100 price target (36% upside potential). No doubt hedge funds are also relieved to hear that Qualcomm has just won a critical partial stay from The Ninth Circuit Court of Appeals. The company won’t have to grant patent licenses to rivals and can still require patent licenses for customers to buy chips while its appeal is ongoing. According to Qualcomm general counsel Don Rosenberg, the company still believes “the district court decision will be overturned once the merits of our appeal have been considered.” In total, QCOM scores a Moderate Buy Street consensus with a $78 average price target. 3\. Hologic (HOLX)Medical tech stock Hologic focuses primarily on women’s health and beauty; it sells medical devices for surgery and medical imaging. During Q2, 14 funds initiated positions in HOLX. RBC Capital reveals that funds now own a total of $748 million in Hologic stock. Of course, Hologic has a history when it comes to hedge funds. Back in 2013, hedge fund activist Carl Icahn swooped in with a 12.63% stake. Three years later he cashed in on what proved to be a successful intervention. “Yesterday our designees resigned from the [Hologic] board because the situation no longer calls for activism,” Icahn wrote on Twitter at the time. “Hologic is the quintessential example of activism at its best. We commend [Hologic chief executive] Steve MacMillan for a job well done.”Looking ahead, analysts are divided over HOLX’s outlook. Five analysts currently rate the stock a buy, while four analysts are staying on the sidelines. “Hologic is gradually executing over the course of this year as its breast health and molecular diagnostics businesses pace its growth, but are offset by slower growth or declining segments” states Canaccord Genuity’s Mark Massaro. This Top 50 analyst reiterated his hold rating on Hologic on August 1, but ramped up the price target from $49 to $52 (8% upside potential). “Near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide” he explained. 4\. United Technologies Corp (UTX)Like the previous two stocks, United Technologies Corp saw the addition of 14 new funds in Q2. This aerospace and defense stock now features in 16% of the portfolios scanned by RBC Capital. And the total hedge fund holding is valued at $4,552 million.Encouragingly, analysts are positive on UTX right now. The stock boasts a ‘Strong Buy’ consensus, and a price target that indicates 23% upside from current levels. Indeed, both Vertical Research and Seaport Global upgraded United Technologies from Hold to Buy in the last couple of months.The analysts made their calls after the news of a proposed $120 billion merger between UTX and Raytheon (RTN) sent shares plummeting. The deal, which is set to close in the first half of the year, is currently undergoing an investigated by the U.S. Department of Justice’s antitrust division. According to Vertical Research analyst Jeffrey Sprague the stock’s weakness created an attractive buying opportunity.More recently, five-star Cowen & Co analyst Cai Rumohr reiterated his UTX buy rating and $150 price target. Turning the cash flow corner, enthused Rumohr following Q2 earnings. “Q2's EPS/cash flow beat suggests cash consuming build in new aerospace programs is starting to reverse with a likely multi-year ramp in standalone CFPS [cash flow per share]. And the proposed RTN merger would accelerate cash deployment potential” summed up the analyst. 5\. Roper Technologies (ROP) Roper Technologies is a diversified industrial company that produces engineered products for global niche markets. That includes everything from creative software technologies for visual effects and 3D content, to safety valves and radiotherapy solutions. Thirteen hedge funds started new positions in Roper during Q2, says RBC Capital.Indeed, the firm’s own Deane Dray shares this bullish outlook on Roper stock. He recently reiterated his buy rating while bumping up the price target from $391 to $393 (13% upside potential). “Outperform-rated Roper’s modest 2Q19 beat featured its typical high quality of earnings” Dray wrote post-earnings. However, the analyst added that there was a pang of disappointment with the disclosure that expected 2H19 slowing in short- cycle industrial businesses (8% of revenues) could pose a -10c headwind. Ultimately, though, Roper remains “indisputably one of the highest-quality names within the Multi-Industry sector.” It leads the pack in EBIT margin and free cash flow conversion thanks to its portfolio of low- capital-intensity and profitable SaaS and network businesses, he tells investors. Currently five analysts rate ROP a buy, with only 1 analyst calling the stock a hold- giving it a ‘Strong Buy’ consensus. Meanwhile the average analyst price target stands at $399 suggesting shares can climb 15% in the coming months. Find analysts' favorite stocks with the Top Analysts' Stocks tool

  • Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet
    Simply Wall St.

    Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GuruFocus.com

    Hologic Inc (HOLX) Chairman, President and CEO Stephen P Macmillan Sold $9.5 million of Shares

    Chairman, President and CEO of Hologic Inc (30-Year Financial, Insider Trades) Stephen P Macmillan (insider trades) sold 194,396 shares of HOLX on 08/05/2019 at an average price of $48.77 a share. Continue reading...

  • DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
    Zacks

    DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

    DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Hologic Looks Good as Long as the Stock Doesn't Close Below This Key Level
    TheStreet.com

    Hologic Looks Good as Long as the Stock Doesn't Close Below This Key Level

    In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Steve MacMillan, president and CEO of Hologic Inc. , the medical equipment maker with shares up 24% for the year. MacMillan explained that Hologic's 3D mammography and cervical products are designed to detect cancers earlier, so patients get better outcomes and the health care system overall saves money. In the daily bar chart of HOLX, below, we can see that prices have moved up so far this year but not without a number of retracements or corrections along the way.

  • MoneyShow

    Acute Care and Women's Health- Breakout Buys in Healthcare

    Leo Fasciocco specializes in stocks that have broken out of technical bases; the editor of Ticker Tape Digest reviews two recent buys in the healthcare sector. Both have recently broken out to new all-time highs.

  • Hologic Acquires Approximately 46% of Shares in SuperSonic Imagine, a French Innovator in Ultrasound Medical Imaging
    Business Wire

    Hologic Acquires Approximately 46% of Shares in SuperSonic Imagine, a French Innovator in Ultrasound Medical Imaging

    Hologic, Inc. (HOLX), a global leader in women’s health, and SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialized in ultrasound medical imaging, jointly announce today that Hologic Hub Ltd, a wholly-owned indirect subsidiary of Hologic, Inc., has acquired approximately 46% of SuperSonic Imagine shares, pursuant to a shares sale agreement entered into today. “We are very pleased to take this important step in the process of acquiring SuperSonic Imagine, and are excited to begin integrating the company’s best-in-class ultrasound technology, products and people with Hologic’s broader resources for the benefit of women’s breast health,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. SuperSonic Imagine’s main shareholders, namely Bpifrance, Andera Partners, Auriga Partners, Mérieux Participations and CDC PME Croissance, holding together 10,841,409 shares, representing approximately 46% of the outstanding share capital of SuperSonic Imagine, sold all of their shares to Hologic at a price of €1.50 per share.

  • Business Wire

    Hologic to Webcast Presentation at the Canaccord Genuity 39th Annual Growth Conference

    Hologic, Inc. announced today that the Company will present at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Wednesday, August 7 at 10 a.m. Eastern Time.

  • Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View
    Zacks

    Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View

    Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.

  • Hologic Inc (HOLX) Q3 2019 Earnings Call Transcript
    Motley Fool

    Hologic Inc (HOLX) Q3 2019 Earnings Call Transcript

    HOLX earnings call for the period ending June 30, 2019.

  • Benzinga

    A Preview Of Hologic's Q3 Earnings

    Hologic (NASDAQ: HOLX ) unveils its next round of earnings this Wednesday, July 31. Get prepared with Benzinga's ultimate preview for Hologic's Q3 earnings. Earnings and Revenue Analysts expect Hologic ...

  • Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
    Zacks

    Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

    Solid growth in emerging markets is expected to be an added positive this earnings season.

  • Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
    Zacks

    Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

    Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

  • GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand
    Zacks

    GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

    GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.

  • Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
    Zacks

    Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

    Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

  • Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
    Zacks

    Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

    Omnicell (OMCL) aims at product innovation through R&D.

  • Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
    Zacks

    Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

    Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.

  • Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
    Zacks

    Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

    Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

  • Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
    Zacks

    Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand

    It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.